| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Fralex Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dainippon Sumitomo Pharma America Holdings is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
One of the leading health care sources in the nation. We offer certified, medical grade supplies worldwide. info@crowdhealth.org